Cancer Epidemiology Biomarkers & Prevention, Vol 4, Issue 6 655-659, Copyright © 1995 by American Association for Cancer Research

ARTICLES

Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men

EH Corder, GD Friedman, JH Vogelman and N Orentreich
Center for Demographic Studies, Duke University, Durham, North Carolina 27708, USA.

Our previous study provided evidence that higher serum levels of the active form of vitamin D, 1,25-dihydroxyvitamin D (1, 25-D), might possibly slow the progression of subclinical to clinically significant prostate cancer in both black and white men, especially after age 57. This paper extends the prior study by contrasting seasonal variation in 1,25-D and its precursor, 25-hydroxyvitamin D (25-D), in case and control subjects. In addition, the risk of prostate cancer is related to serum levels of vitamin D-binding protein (VDBP) and total dehydroepiandrosterone and to polymorphic variation in VDBP. The expected elevated summer levels of 25-D were seen in case and control subjects and, as expected, 1,25-D did not vary throughout the year in the control subjects. Unexpectedly, lower case levels of 1,25-D were limited largely to the summer months (P = 0.01) in both black and white cases and to cases greater than or equal to the median age of 57 years. Levels of VDBP and dehydroepiandrosterone and the frequencies of VDBP polymorphisms were similar in case and control subjects, although striking differences were seen in allelic frequencies in black and white men. These observations provide additional evidence that vitamin D metabolism may impact the risk of prostate cancer.

This article has been cited by other articles:

				E. Hormones and Prostate Cancer Collaborative Group Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies J Natl Cancer Inst, February 6, 2008; 100(3): 170 - 183. [Abstract] [Full Text] [PDF]

				Y. Park, P. N. Mitrou, V. Kipnis, A. Hollenbeck, A. Schatzkin, and M. F. Leitzmann Calcium, Dairy Foods, and Risk of Incident and Fatal Prostate Cancer: The NIH-AARP Diet and Health Study Am. J. Epidemiol., December 1, 2007; 166(11): 1270 - 1279. [Abstract] [Full Text] [PDF]

				C. K. Cross, D. Shultz, S. B. Malkowicz, W. C. Huang, R. Whittington, J. E. Tomaszewski, A. A. Renshaw, J. P. Richie, and A. V. D'Amico Impact of Race on Prostate-Specific Antigen Outcome After Radical Prostatectomy for Clinically Localized Adenocarcinoma of the Prostate J. Clin. Oncol., June 15, 2002; 20(12): 2863 - 2868. [Abstract] [Full Text] [PDF]

				K. A. Nelson and J. S. Witte Androgen Receptor CAG Repeats and Prostate Cancer Am. J. Epidemiol., May 15, 2002; 155(10): 883 - 890. [Abstract] [Full Text] [PDF]

				K. A. Moffatt, W. U. Johannes, T. E. Hedlund, and G. J. Miller Growth Inhibitory Effects of 1{alpha}, 25-Dihydroxyvitamin D3 Are Mediated by Increased Levels of p21 in the Prostatic Carcinoma Cell Line ALVA-31 Cancer Res., October 1, 2001; 61(19): 7122 - 7129. [Abstract] [Full Text] [PDF]

				M. C. Bosland Chapter 2: The Role of Steroid Hormones in Prostate Carcinogenesis J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 39 - 66. [Abstract] [Full Text] [PDF]

				P. J. Russell, S. Bennett, and P. Stricker Growth factor involvement in progression of prostate cancer Clin. Chem., April 1, 1998; 44(4): 705 - 723. [Abstract] [Full Text] [PDF]